| |
Article Title |
Author(s) |
Type (Status) |
Available Online |
|
Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer
DOI: 10.1016/j.ejca.2012.04.014
Abstract: Background: Sequential chemotherapy and individualised accelerated radiotherapy (INDAR) has been shown to be effective in non-small cell lung cancer (NSCLC), allowing delivering of high biol...
|
Angela van Baardwijk,
Bart Reymen,
Stofferinus Wanders,
Jacques Borger,
Michel Öllers,
Anne-Marie C. Dingemans,
Gerben Bootsma,
Wiel Geraedts,
Cordula Pitz,
Ragnar Lunde,
Frank Peters,
Philippe Lambin,
Dirk De Ruysscher
et al.
|
Full-length article
(In Press Corrected Proof)
|
21 May 2012 |
|
NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
DOI: 10.1016/j.ejca.2012.04.011
Abstract: Purpose: NovoTTF-100A is a portable device delivering low-intensity, intermediate frequency electric fields via non-invasive, transducer arrays. Tumour Treatment Fields (TTF), a completely n...
|
Roger Stupp,
Eric T. Wong,
Andrew A. Kanner,
David Steinberg,
Herbert Engelhard,
Volkmar Heidecke,
Eilon D. Kirson,
Sophie Taillibert,
Frank Liebermann,
Vladimir Dbalý,
Zvi Ram,
J. Lee Villano,
Nikolai Rainov,
Uri Weinberg,
David Schiff,
Lara Kunschner,
Jeffrey Raizer,
Jerome Honnorat,
Andrew Sloan,
Mark Malkin,
Joseph C. Landolfi,
Franz Payer,
Maximilian Mehdorn,
Robert J. Weil,
Susan C. Pannullo,
Manfred Westphal,
Martin Smrcka,
Lawrence Chin,
Herwig Kostron,
Silvia Hofer,
Jeffrey Bruce,
Rees Cosgrove,
Nina Paleologous,
Yoram Palti,
Philip H. Gutin
et al.
|
Full-length article
(In Press Corrected Proof)
|
21 May 2012 |
|
Higher prevalence of sexual dysfunction in colon and rectal cancer survivors compared with the normative population: A population-based study
DOI: 10.1016/j.ejca.2012.04.004
Abstract: Background: To compare colorectal cancer survivors with a normative population regarding erectile dysfunction, ejaculation problems, dyspareunia, dry vagina, sexual functioning (SF) and enjo...
|
B.L. Den Oudsten,
M.J. Traa,
M.S.Y. Thong,
H. Martijn,
I.H.J.T. De Hingh,
K. Bosscha,
L.V. van de Poll-Franse
et al.
|
Full-length article
(In Press Corrected Proof)
|
21 May 2012 |
|
Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function
DOI: 10.1016/j.ejca.2012.04.002
Abstract: Background: Cisplatin-based combination chemotherapy is the mainstay of treatment for locally advanced or metastatic urothelial carcinoma. However, standard dose schedule of cisplatin cannot...
|
Rafael Morales-Barrera,
Joaquim Bellmunt,
Cristina Suárez,
Claudia Valverde,
Marta Guix,
Cesar Serrano,
Manuel Gallén,
Joan Carles
et al.
|
Full-length article
(In Press Corrected Proof)
|
18 May 2012 |
|
Quality-of-life among head and neck cancer survivors at one year after treatment – A systematic review
DOI: 10.1016/j.ejca.2012.04.005
Abstract: Background: The importance of quality-of-life (QoL) research has been recognised over the past two decades in patients with head and neck (H&N) cancer. The aims of this systematic review...
|
W.K.W. So,
R.J. Chan,
D.N.S. Chan,
B.G.M. Hughes,
S.Y. Chair,
K.C. Choi,
C.W.H. Chan
et al.
|
Full-length article
(In Press Corrected Proof)
|
14 May 2012 |
|
Clear cell sarcoma of the kidney: A review
DOI: 10.1016/j.ejca.2012.04.009
Abstract: Clear cell sarcoma of the kidney (CCSK) is a rare renal tumour that is observed most often in children under 3years of age. Only a few large series of CCSK have been reported and patients wi...
|
S.L.M. Gooskens,
R. Furtwängler,
G.M. Vujanic,
J.S. Dome,
N. Graf,
M.M. van den Heuvel-Eibrink
et al.
|
Full-length article
(In Press Corrected Proof)
|
14 May 2012 |
|
The EORTC QLQ-OH17: A supplementary module to the EORTC QLQ-C30 for assessment of oral health and quality of life in cancer patients
DOI: 10.1016/j.ejca.2012.04.003
Abstract: Aims: Assessment of oral and dental problems is seldom routine in clinical oncology, despite the potential negative impact of these problems on nutritional status, social function and qualit...
|
Marianne Jensen Hjermstad,
Mia Bergenmar,
Sheila E. Fisher,
Sébastien Montel,
Ourania Nicolatou-Galitis,
Judith Raber-Durlacher,
Susanne Singer,
Irma Verdonck-de Leeuw,
Joachim Weis,
Noam Yarom,
Bente B. Herlofson
et al.
|
Full-length article
(In Press Corrected Proof)
|
10 May 2012 |
|
Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer
DOI: 10.1016/j.ejca.2012.04.007
Abstract: Background: The aim of this study was to compare the performance of the guaiac-based faecal occult blood test (G-FOBT), with that of three immunochemical faecal occult blood tests (I-FOBT) w...
|
J. Faivre,
V. Dancourt,
B. Denis,
E. Dorval,
C. Piette,
Ph. Perrin,
J.M. Bidan,
C. Jard,
S. Jung,
R. Levillain,
J. Viguier,
J.F. Bretagne
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 May 2012 |
|
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
DOI: 10.1016/j.ejca.2012.04.001
Abstract: Aim: Trabectedin in combination with pegylated liposomal doxorubicin (PLD) improves progression-free survival (PFS) compared to PLD alone in recurrent ovarian cancer (J Clin Oncol 2010;28:31...
|
Bradley J. Monk,
Thomas J. Herzog,
Stanley B. Kaye,
Carolyn N. Krasner,
Jan B. Vermorken,
Franco M. Muggia,
Eric Pujade-Lauraine,
Youn C. Park,
Trilok V. Parekh,
Andres M. Poveda
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 April 2012 |
|
Infusion of calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in colorectal cancer: A systematic review and meta-analysis
DOI: 10.1016/j.ejca.2012.03.018
Abstract: Background: It is hypothesised that infusion of calcium and magnesium (Ca/Mg) can reduce the occurrence of oxaliplatin-related sensory neurotoxicity. However, more recent data have drawn a c...
|
Zhenjie Wu,
Jun Ouyang,
Zhenhua He,
Sen Zhang
|
Full-length article
(In Press Corrected Proof)
|
30 April 2012 |
|
Stem cells in breast tumours: Are they ready for the clinic?
DOI: 10.1016/j.ejca.2012.03.019
Abstract: The concept of stem-like cells in cancer has been gaining currency over the last decade or so since evidence for stem cell activity in human leukaemia and solid tumours, including breast can...
|
Matthew P. Ablett,
Jagdeep K. Singh,
Robert B. Clarke
|
Full-length article
(In Press Corrected Proof)
|
30 April 2012 |
|
Specific-site methylation of tumour suppressor ANKRD11 in breast cancer
DOI: 10.1016/j.ejca.2012.03.023
Abstract: ANKRD11 is a putative tumour suppressor gene in breast cancer, which has been shown in our laboratory to be a co-activator of p53. Our data suggest that down-regulation of ANKRD11 is associa...
|
Sue Ping Lim,
Nick C. Wong,
Rachel J. Suetani,
Kristen Ho,
Jane Lee Ng,
Paul M. Neilsen,
Peter G. Gill,
Raman Kumar,
David F. Callen
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 April 2012 |
|
Mammographic changes resulting from benign breast surgery impair breast cancer detection at screening mammography
DOI: 10.1016/j.ejca.2012.03.011
Abstract: Purpose: To study possible explanations for lower screening performance after previous benign breast surgery. Patients and methods: We included a consecutive series of 351,009 screening exam...
|
Vivian van Breest Smallenburg,
Lucien E.M. Duijm,
Adri C. Voogd,
Frits H. Jansen,
Marieke W.J. Louwman
et al.
|
Full-length article
(In Press Corrected Proof)
|
18 April 2012 |
|
Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching
DOI: 10.1016/j.ejca.2012.03.020
Abstract: Background: Even though neoadjuvant chemotherapy has shown no benefits on overall survival (OS), it is being widely used in the treatment of breast cancer. This is based on the assumption th...
|
I. Le Ray,
S. Dabakuyo,
G. Crehange,
M. Bardou,
L. Arnould,
J. Fraisse,
P. Fumoleau,
B. Coudert,
S. Causeret,
P. Arveux,
P. Maingon,
F. Bonnetain
et al.
|
Full-length article
(In Press Corrected Proof)
|
18 April 2012 |
|
Matched-case comparison of neoadjuvant chemotherapy in patients with FIGO stage IB1-IIB cervical cancer to establish selection criteria
DOI: 10.1016/j.ejca.2012.03.015
Abstract: Objective: Neoadjuvant chemotherapy (NACT) for cervical cancer still remains controversial. NACT was evaluated to establish selection criteria. Methods: A matched-case comparison was designe...
|
Ting Hu,
Shuang Li,
Yile Chen,
Jian Shen,
Xiong Li,
Kecheng Huang,
Ru Yang,
Li Wu,
Zhilan Chen,
Yao Jia,
Shaoshuai Wang,
Xiaodong Cheng,
Xiaobing Han,
Zhongqiu Lin,
Hui Xing,
Pengpeng Qu,
Hongbing Cai,
Xiaojie Song,
Xiaoyu Tian,
Hongbing Xu,
Jun Xu,
Qinghua Zhang,
Ling Xi,
Dongrui Deng,
Hui Wang,
Shixuan Wang,
Weiguo Lv,
Changyu Wang,
Xing Xie,
Ding Ma
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 April 2012 |
|
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?
DOI: 10.1016/j.ejca.2012.03.016
Abstract: Background: Two phase III trials of neoadjuvant treatment in T3-4 rectal cancer established that adding chemotherapy (CRT) to radiotherapy (RT) improves pathological complete response (pCR) ...
|
F. Bonnetain,
J.F. Bosset,
J.P. Gerard,
G. Calais,
T. Conroy,
L. Mineur,
O. Bouché,
P. Maingon,
O. Chapet,
L. Radosevic-Jelic,
N. Methy,
L. Collette
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 April 2012 |
|
Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial
DOI: 10.1016/j.ejca.2012.03.013
Abstract: Aims: To identify risk factors for major adverse events (AEs) and to develop a nomogram to predict the probability of such AEs in patients who have surgery for apparent early stage endometri...
|
Srinivas Kondalsamy-Chennakesavan,
Monika Janda,
Val Gebski,
Jannah Baker,
Alison Brand,
Russell Hogg,
Thomas W. Jobling,
Russell Land,
Tom Manolitsas,
Marcelo Nascimento,
Deborah Neesham,
James L. Nicklin,
Martin K. Oehler,
Geoff Otton,
Lewis Perrin,
Stuart Salfinger,
Ian Hammond,
Yee Leung,
Peter Sykes,
Hextan Ngan,
Andrea Garrett,
Michael Laney,
Tong Yow Ng,
Karfai Tam,
Karen Chan,
David H. Wrede,
Selvan Pather,
Bryony Simcock,
Rhonda Farrell,
Gregory Robertson,
Graeme Walker,
Anthony McCartney,
Andreas Obermair
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 April 2012 |
|
Prediction of prognosis after trimodal therapy in patients with locally advanced squamous cell carcinoma of the oesophagus
DOI: 10.1016/j.ejca.2012.03.010
Abstract: Background: Due to the poor prognosis of locally advanced oesophageal cancer, predictive markers are warranted to better select patients who may benefit from multimodal therapy. Patients and...
|
Michael Stahl,
Nils Lehmann,
Martin K. Walz,
Martin Stuschke,
Hansjochen Wilke
et al.
|
Full-length article
(In Press Corrected Proof)
|
13 April 2012 |
|
Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome
DOI: 10.1016/j.ejca.2012.03.012
Abstract: Background: Mammalian target of rapamycin (mTOR) inhibitors are approved for use in patients with metastatic renal cell carcinoma (mRCC) and are under investigation in several other malignan...
|
Donnette A. Dabydeen,
Jyothi P. Jagannathan,
Nikhil Ramaiya,
Katherine Krajewski,
Fabio A.B. Schutz,
Daniel C. Cho,
Ivan Pedrosa,
Toni K. Choueiri
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 April 2012 |
|
Mastectomy trends for early-stage breast cancer: A report from the EUSOMA multi-institutional European database
DOI: 10.1016/j.ejca.2012.03.008
Abstract: Introduction: Recent single-institution reports have shown increased mastectomy rates during the last decade. Further studies aiming to determine if these reports could be reflecting a natio...
|
Carlos A. Garcia-Etienne,
Mariano Tomatis,
Joerg Heil,
Kay Friedrichs,
Rolf Kreienberg,
Andreas Denk,
Marion Kiechle,
Fatemeh Lorenz-Salehi,
Rainer Kimmig,
Günter Emons,
Mahmoud Danaei,
Volker Heyl,
Uwe Heindrichs,
Christoph J. Rageth,
Wolfgang Janni,
Lorenza Marotti,
Marco Rosselli del Turco,
Antonio Ponti,
eusomaDB Working Group
et al.
|
Full-length article
(In Press Corrected Proof)
|
06 April 2012 |
|
Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations
DOI: 10.1016/j.ejca.2012.02.049
Abstract: KIT aberrations predict the outcome of targeted therapies in acrolentiginous (ALM) and mucosal (MM) melanoma patients. KIT immunoreactivity and mutation status was assessed in 41 ALM and 25 ...
|
Nicola L. Schoenewolf,
Christian Bull,
Benedetta Belloni,
David Holzmann,
Sabina Tonolla,
Roland Lang,
Daniela Mihic-Probst,
Christian Andres,
Reinhard Dummer
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 April 2012 |
|
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study)
DOI: 10.1016/j.ejca.2012.03.003
Abstract: Objective: To describe patterns of healthcare resource utilisation and associated costs for patients with advanced melanoma in the United Kingdom (UK), Italy, and France. Methods: For patien...
|
K. Johnston,
A.R. Levy,
P. Lorigan,
M. Maio,
C. Lebbe,
M. Middleton,
A. Testori,
C. Bédane,
C. Konto,
A. Dueymes,
U. Sbarigia,
M. van Baardewijk
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 April 2012 |
|
Early discontinuation of tamoxifen intake in younger women with breast cancer: Is it time to rethink the way it is prescribed?
DOI: 10.1016/j.ejca.2012.03.004
Abstract: Background: Tamoxifen is the main recommended adjuvant hormonal treatment for premenopausal women with hormone-responsive early breast cancer. Little data is available on compliance and pers...
|
Laetitia Huiart,
Anne-Déborah Bouhnik,
Dominique Rey,
Carole Tarpin,
Camille Cluze,
Marc Karim Bendiane,
Patrice Viens,
Roch Giorgi
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 April 2012 |
|
Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysis
DOI: 10.1016/j.ejca.2012.03.001
Abstract: Background: The prognostic significance of p53 aberration in hepatocellular carcinoma (HCC) remains inconclusive. This systematic review and meta-analysis aimed to provide comprehensive evid...
|
Jiangbo Liu,
Qingyong Ma,
Min Zhang,
Xinshuai Wang,
Dong Zhang,
Wei Li,
Fengfei Wang,
Erxi Wu
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 March 2012 |
|
MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in Southern European populations: Results from a Meta-analysis
DOI: 10.1016/j.ejca.2012.03.006
Abstract: Background and methods: Seven genetic biomarkers previously associated with melanoma were analysed in a meta-analysis conducted in three South European populations: five red hair colour (RHC...
|
Maider Ibarrola-Villava,
Hui-Han Hu,
Mickaël Guedj,
Lara P. Fernandez,
Vincent Descamps,
Nicole Basset-Seguin,
Martine Bagot,
Armand Benssussan,
Philippe Saiag,
Maria Concetta Fargnoli,
Ketty Peris,
Jose A. Aviles,
Ana Lluch,
Gloria Ribas,
Nadem Soufir
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 March 2012 |
|
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer
DOI: 10.1016/j.ejca.2012.03.002
Abstract: Background: Endocrine therapy is the preferred treatment for hormone-receptor (HR) positive metastatic breast cancer. In premenopausal patients, ovarian function suppression with goserelin i...
|
Rupert Bartsch,
Zsuzsanna Bago-Horvath,
Anna Berghoff,
Catharina DeVries,
Ursula Pluschnig,
Peter Dubsky,
Margaretha Rudas,
Robert M. Mader,
Andrea Rottenfusser,
Florian Fitzal,
Michael Gnant,
Christoph C. Zielinski,
Guenther G. Steger
et al.
|
Full-length article
(In Press Corrected Proof)
|
29 March 2012 |
|
Enhancing the anticancer effect of the histone deacetylase inhibitor by activating transglutaminase
DOI: 10.1016/j.ejca.2012.02.067
Abstract: Histone deacetylase (HDAC) inhibitors have shown promising anticancer effects in clinical trials. However, a proportion of patients do not respond to HDAC inhibitor therapy. We have previous...
|
Dora Ling,
Glenn M. Marshall,
Pei Y. Liu,
Ning Xu,
Charlotte A. Nelson,
Siiri E. Iismaa,
Tao Liu
et al.
|
Full-length article
(In Press Corrected Proof)
|
29 March 2012 |
|
TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells
DOI: 10.1016/j.ejca.2012.03.005
Abstract: Most gastric cancer cells are resistant to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Since TRAIL resistance is associated with lipid rafts, in which both death recept...
|
Ling Xu,
Ye Zhang,
Jing Liu,
Jinglei Qu,
Xuejun Hu,
Fan Zhang,
Huachuan Zheng,
Xiujuan Qu,
Yunpeng Liu
et al.
|
Full-length article
(In Press Corrected Proof)
|
29 March 2012 |
|
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
DOI: 10.1016/j.ejca.2012.02.057
Abstract: Background: The CRYSTAL and OPUS randomised clinical trials demonstrated that adding cetuximab to first-line chemotherapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC) ...
|
Carsten Bokemeyer,
Eric Van Cutsem,
Philippe Rougier,
Fortunato Ciardiello,
Steffen Heeger,
Michael Schlichting,
Ilhan Celik,
Claus-Henning Köhne
et al.
|
Full-length article
(In Press Corrected Proof)
|
27 March 2012 |
|
Excess body weight and the risk of primary liver cancer: An updated meta-analysis of prospective studies
DOI: 10.1016/j.ejca.2012.02.063
Abstract: Aims: To provide a quantitative assessment of the association between excess body weight (EBW) and the risk of primary liver cancer (PLC), we performed an updated meta-analysis of prospectiv...
|
Yi Chen,
Xiaolin Wang,
Jianhua Wang,
Zhiping Yan,
Jianjun Luo
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 March 2012 |
|
Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer
DOI: 10.1016/j.ejca.2012.02.051
Abstract: Introduction: Locoregional recurrence (LRR) after breast-conserving therapy is a well-known independent risk factor associated with unfavourable long-term outcome. Controversy exists concern...
|
E. Tanis,
C.J.H. van de Velde,
H. Bartelink,
M.J. van de Vijver,
H. Putter,
J.A. van der Hage
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 March 2012 |
|
Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the International Lung Cancer Consortium
DOI: 10.1016/j.ejca.2012.01.038
Abstract: Background and methods: Familial aggregation of lung cancer exists after accounting for cigarette smoking. However, the extent to which family history affects risk by smoking status, histolo...
|
Michele L. Coté,
Mei Liu,
Stefano Bonassi,
Monica Neri,
Ann G. Schwartz,
David C. Christiani,
Margaret R. Spitz,
Joshua E. Muscat,
Gad Rennert,
Katja K. Aben,
Angeline S. Andrew,
Vladimir Bencko,
Heike Bickeböller,
Paolo Boffetta,
Paul Brennan,
Hermann Brenner,
Eric J. Duell,
Eleonora Fabianova,
John K. Field,
Lenka Foretova,
Søren Friis,
Curtis C. Harris,
Ivana Holcatova,
Yun-Chul Hong,
Dolores Isla,
Vladimir Janout,
Lambertus A. Kiemeney,
Chikako Kiyohara,
Qing Lan,
Philip Lazarus,
Jolanta Lissowska,
Loic Le Marchand,
Dana Mates,
Keitaro Matsuo,
Jose I. Mayordomo,
John R. McLaughlin,
Hal Morgenstern,
Heiko Müeller,
Irene Orlow,
Bernard J. Park,
Mila Pinchev,
Olaide Y. Raji,
Hedy S. Rennert,
Peter Rudnai,
Adeline Seow,
Isabelle Stucker,
Neonila Szeszenia-Dabrowska,
M. Dawn Teare,
Anne Tjønnelan,
Donatella Ugolini,
Henricus F.M. van der Heijden,
Erich Wichmann,
John K. Wiencke,
Penella J. Woll,
Ping Yang,
David Zaridze,
Zuo-Feng Zhang,
Carol J. Etzel,
Rayjean J. Hung
et al.
|
Full-length article
(In Press Corrected Proof)
|
21 March 2012 |
|
Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection – Results from a clinic-based longitudinal cohort
DOI: 10.1016/j.ejca.2012.02.065
Abstract: Background: Although serum level of alpha-fetoprotein (AFP) has long been used to complement imaging tests in the screening and diagnosis of hepatocellular carcinoma (HCC), whether it can be...
|
Hie-Won Hann,
Xiaoying Fu,
Ronald E. Myers,
Richard S. Hann,
Shaogui Wan,
Su Hee Kim,
Natalie Au,
Jinliang Xing,
Hushan Yang
et al.
|
Full-length article
(In Press Corrected Proof)
|
21 March 2012 |
|
Cancer screening and health system resilience: Keys to protecting and bolstering preventive services during a financial crisis
DOI: 10.1016/j.ejca.2012.02.060
Abstract: The aim of this paper is to elucidate the rationale for sustaining and expanding cost-effective, population-based screening services for breast, cervical and colorectal cancers in the contex...
|
Jose M. Martin-Moreno,
Ahti Anttila,
Lawrence von Karsa,
Jose L. Alfonso-Sanchez,
Lydia Gorgojo
et al.
|
Full-length article
(In Press Corrected Proof)
|
19 March 2012 |
|
Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells
DOI: 10.1016/j.ejca.2012.02.062
Abstract: We previously showed that methyl-F-anandamide, a stable analogue of the anandamide, inhibited the growth and the progression of cultured human breast cancer cells. As accumulating evidences ...
|
Chiara Laezza,
Alba D’Alessandro,
Simona Paladino,
Anna Maria Malfitano,
Maria Chiara Proto,
Patrizia Gazzerro,
Simona Pisanti,
Antonietta Santoro,
Elena Ciaglia,
Maurizio Bifulco,
Endocannabinoid Research Group
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 March 2012 |
|
Effects of the combination of RAD001 and docetaxel on breast cancer stem cells
DOI: 10.1016/j.ejca.2012.02.053
Abstract: Recent evidence has suggested that breast cancer contains a rare population of cells called cancer stem cells (CSCs), which have an extensive self-renewal ability and contribute to metastasi...
|
Xiaobei Zhang,
Sheng Zhang,
Yan Liu,
Jingjing Liu,
Yi Ma,
Yuanxi Zhu,
Jin Zhang
et al.
|
Full-length article
(In Press Corrected Proof)
|
15 March 2012 |
|
Population attributable risk of aflatoxin-related liver cancer: Systematic review and meta-analysis
DOI: 10.1016/j.ejca.2012.02.009
Abstract: Background: Over 4 billion people worldwide are exposed to dietary aflatoxins, which cause liver cancer (hepatocellular carcinoma, HCC) in humans. However, the population attributable risk (...
|
Yan Liu,
Chung-Chou H. Chang,
Gary M. Marsh,
Felicia Wu
|
Full-length article
(In Press Corrected Proof)
|
14 March 2012 |
|
Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
DOI: 10.1016/j.ejca.2012.02.059
Abstract: Aim: To use published literature and experts’ opinion to investigate the clinical meaning and magnitude of changes in the Quality of Life (QOL) of groups of patients measured with the Europe...
|
K. Cocks,
M.T. King,
G. Velikova,
G. de Castro,
M. Martyn St-James,
P.M. Fayers,
J.M. Brown
et al.
|
Full-length article
(In Press Corrected Proof)
|
14 March 2012 |
|
miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2
DOI: 10.1016/j.ejca.2012.02.007
Abstract: MicroRNAs are strongly implicated in cancer but their specific roles and functions in the major cancers have yet to be fully elucidated. In this study, we defined the expression and function...
|
Lingchao Chen,
Xiaofeng Wang,
Hanbing Wang,
Yongli Li,
Wei Yan,
Lei Han,
Kailiang Zhang,
Junxia Zhang,
Yongzhi Wang,
Yan Feng,
Peiyu Pu,
Tao Jiang,
Chunsheng Kang,
Chuanlu Jiang
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 March 2012 |
|
Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort
DOI: 10.1016/j.ejca.2012.02.002
Abstract: Background: Prediction models need validation to assess their value outside the development setting. Objective: To assess the external validity of the European Randomised study of Screening ...
|
Heidi A. van Vugt,
Ries Kranse,
Ewout W. Steyerberg,
Henk G. van der Poel,
Martijn Busstra,
Paul Kil,
Eric H. Oomens,
Igle J. de Jong,
Chris H. Bangma,
Monique J. Roobol
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 March 2012 |
|
Opposite effects of microchimerism on breast and colon cancer
DOI: 10.1016/j.ejca.2012.02.006
Abstract: Background: Detection of Y chromosome, thought to originate from previous pregnancies with a male fetus, is common in women. Lower concentrations have been reported in women with breast canc...
|
Mads Kamper-Jørgensen,
Robert J. Biggar,
Anne Tjønneland,
Henrik Hjalgrim,
Niels Kroman,
Klaus Rostgaard,
Casey L. Stamper,
Anja Olsen,
Anne-Marie N. Andersen,
Vijayakrishna K. Gadi
et al.
|
Full-length article
(In Press Corrected Proof)
|
07 March 2012 |
|
Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells
DOI: 10.1016/j.ejca.2012.01.032
Abstract: The multitargeted tyrosine-kinase inhibitor sunitinib is a highly effective anti-angiogenic and cytostatic agent in the therapy of various tumours. While malignant gliomas have been shown to...
|
Nadine Andrae,
Elmar Kirches,
Roland Hartig,
Daniela Haase,
Gerburg Keilhoff,
Thomas Kalinski,
Christian Mawrin
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 March 2012 |
|
Successful centralisation of patients with vulvar carcinoma: A population-based study in The Netherlands
DOI: 10.1016/j.ejca.2012.01.030
Abstract: Introduction: In general, centralisation of care for patients with rare malignancies is advised in order to improve outcome with respect to prognosis and treatment related morbidity. Therefo...
|
Loes C.G. van den Einden,
Katja K.H. Aben,
Leon F.A.G. Massuger,
Dick Johan van Spronsen,
Joanne A. de Hullu
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 March 2012 |
|
Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies
DOI: 10.1016/j.ejca.2011.12.034
Abstract: Introduction: 3-Hydroxy-methylglutaryl coenzyme-A reductase inhibitors (statins) improve survival following pelvic irradiation for cancer. Large studies suggest that patients with hypertensi...
|
Linda J. Wedlake,
Foteini Silia,
Barbara Benton,
Amyn Lalji,
Karen Thomas,
David P. Dearnaley,
Peter Blake,
Diana Tait,
Vincent S. Khoo,
H. Jervoise N. Andreyev
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 March 2012 |
|
High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion
DOI: 10.1016/j.ejca.2012.02.005
Abstract: Purpose: Galectin-1 (Gal-1) is a 14-kDa laminin-binding galectin involved in several biological events including regulation of tumour proliferation and metastasis. In this study, we investig...
|
Ha-Jeong Kim,
Hye-Kyung Jeon,
Young Jae Cho,
Young Ae Park,
Jung-Joo Choi,
In-Gu Do,
Sang Young Song,
Yoo-Young Lee,
Chel Hun Choi,
Tae-Joong Kim,
Duk-Soo Bae,
Jeong-Won Lee,
Byoung-Gie Kim
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 March 2012 |
|
Incidence of fractures causing hospitalisation in prostate cancer patients: Results from the population-based PCBaSe Sweden
DOI: 10.1016/j.ejca.2012.01.035
Abstract: Background: Prostate cancer patients have an increased risk of fractures as a consequence of skeletal metastases and osteoporosis induced by endocrine treatment. Data on incidence of fractur...
|
Andreas Thorstenson,
Ola Bratt,
Olof Akre,
Henrik Hellborg,
Lars Holmberg,
Mats Lambe,
Anna Bill-Axelson,
Pär Stattin,
Jan Adolfsson
et al.
|
Full-length article
(In Press Corrected Proof)
|
02 March 2012 |
|
Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
DOI: 10.1016/j.ejca.2012.01.031
Abstract: Objectives: The aim of this study was to investigate the impact of surgical approach, the extent of surgery and chemotherapy on overall survival in patients with ovarian carcinoma (OC) stage...
|
Claes G. Tropé,
Mari B. Elstrand,
Berit Sandstad,
Ben Davidson,
Halldis Oksefjell
et al.
|
Full-length article
(In Press Corrected Proof)
|
01 March 2012 |
|
Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth
DOI: 10.1016/j.ejca.2012.01.037
Abstract: Genomic aberrations of key regulators of the apoptotic pathway have hardly been identified in neuroblastoma. We detected high BCL2 mRNA and protein levels in the majority of neuroblastoma tu...
|
Fieke Lamers,
Linda Schild,
Ilona J.M. den Hartog,
Marli E. Ebus,
Ellen M. Westerhout,
Ingrid Ora,
Jan Koster,
Rogier Versteeg,
Huib N. Caron,
Jan J. Molenaar
et al.
|
Full-length article
(In Press Corrected Proof)
|
27 February 2012 |
|
Modest improvement in 20 years of kidney cancer care in the Netherlands
DOI: 10.1016/j.ejca.2012.01.033
Abstract: Aim: For an evaluation of the progress achieved in the field of kidney cancer care in the Netherlands in the last decades, we described trends in incidence, treatment, mortality and relative...
|
Saskia A.M. van de Schans,
Katja K.H. Aben,
Peter F.A. Mulders,
John B.A.G. Haanen,
Carla van Herpen,
Rob H.A. Verhoeven,
Henrike E. Karim-Kos,
Egbert Oosterwijk,
Lambertus A.L.M. Kiemeney
et al.
|
Full-length article
(In Press Corrected Proof)
|
27 February 2012 |
|
Carcinoma of endocrine organs: Results of the RARECARE project
DOI: 10.1016/j.ejca.2012.01.029
Abstract: The rarity or the asymptomatic character of endocrine tumours results in a lack of epidemiological studies on their incidence and survival patterns. The aim of this study was to describe the...
|
Jan Maarten van der Zwan,
Sandra Mallone,
Boukje van Dijk,
Magdalena Bielska-Lasota,
Renée Otter,
Roberto Foschi,
Eric Baudin,
Thera P. Links,
The RARECARE WG
et al.
|
Full-length article
(In Press Corrected Proof)
|
24 February 2012 |
|
Is there a general autoantibody signature for cancer?
DOI: 10.1016/j.ejca.2012.01.017
Abstract: Background: There is longstanding evidence for the diagnostic potential of single autoantibodies for cancer and other diseases and more recently for the potential of complex autoantibody sig...
|
Nicole Ludwig,
Andreas Keller,
Petra Leidinger,
Christian Harz,
Christina Backes,
Hans-Peter Lenhof,
Eckart Meese
et al.
|
Full-length article
(In Press Corrected Proof)
|
24 February 2012 |
|
Embryonal cancers in Europe
DOI: 10.1016/j.ejca.2011.12.027
Abstract: Embryonal cancers are a heterogeneous group of rare cancers which mainly occur in children and adolescents. The aim of the present study was to estimate the burden (incidence, prevalence, su...
|
Gemma Gatta,
Andrea Ferrari,
Charles A. Stiller,
Guido Pastore,
Gianni Bisogno,
Annalisa Trama,
Riccardo Capocaccia,
The RARECARE Working Group
et al.
|
Full-length article
(In Press Corrected Proof)
|
22 February 2012 |
|
Trends of cutaneous squamous cell carcinoma in the Netherlands: Increased incidence rates, but stable relative survival and mortality 1989–2008
DOI: 10.1016/j.ejca.2012.01.003
Abstract: Background: Incidence rates of cutaneous squamous cell carcinoma (SCC) are increasing in many countries, though detailed information is scarce. Objectives: To describe detailed trends in inc...
|
L.M. Hollestein,
E. de Vries,
T. Nijsten
|
Full-length article
(In Press Corrected Proof)
|
20 February 2012 |
|
Does baseline total testosterone improve the yielding of prostate cancer screening?
DOI: 10.1016/j.ejca.2012.01.025
Abstract: Previous studies suggest an association between total testosterone (tT) and prostate cancer, but results are conflicting and it is not clear if accounting for the tT levels improves the yiel...
|
Francisco Botelho,
Francisco Pina,
Luís Figueiredo,
Francisco Cruz,
Nuno Lunet
et al.
|
Full-length article
(In Press Corrected Proof)
|
20 February 2012 |
|
Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: Analysis of response and progression-free survival in the RECORD-1 study
DOI: 10.1016/j.ejca.2012.01.027
Abstract: Background and objectives: Objective response as determined by Response Evaluation Criteria in Solid Tumors (RECIST) is low among patients with metastatic renal cell carcinoma (mRCC) treated...
|
Stéphane Oudard,
Rokhaya Thiam,
Laure S. Fournier,
Jacques Medioni,
Michele Lamuraglia,
Florian Scotte,
Elizabeth Fabre,
Dennis Kim,
Euloge Kpamegan,
Ashok Panneerselvam,
Charles A. Cuenod
et al.
|
Full-length article
(In Press Corrected Proof)
|
20 February 2012 |
|
Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer
DOI: 10.1016/j.ejca.2011.12.029
Abstract: This study explored whether the expression of aldehyde dehydrogenase 1 (ALDH1A1) in the primary tumour correlated with lymph node metastasis (LNM) of squamous cell carcinoma of the head and ...
|
Jing Xu,
Susan Müller,
Sreenivas Nannapaneni,
Lin Pan,
Yuxiang Wang,
Xianghong Peng,
Dongsheng Wang,
Mourad Tighiouart,
Zhengjia Chen,
Nabil F. Saba,
Jonathan J. Beitler,
Dong M. Shin,
Zhuo (Georgia) Chen
et al.
|
Full-length article
(In Press Corrected Proof)
|
17 February 2012 |
|
TIS21/BTG2/PC3 enhances downregulation of c-Myc during differentiation of HL-60 cells by activating Erk1/2 and inhibiting Akt in response to all-trans-retinoic acid
DOI: 10.1016/j.ejca.2012.01.028
Abstract: Mouse 12-O-tetradecanoyl phorbol-13-acetate inducible sequence 21 (TIS21), an orthologue of human B-cell translocation gene 2 (BTG2) and rat PC3, is a tumour suppressor that belongs to the a...
|
Muhammad Imran,
Tae Jun Park,
In Kyoung Lim
|
Full-length article
(In Press Corrected Proof)
|
16 February 2012 |
|
Cancer risk and prevention in a globalised world: Solving the public policy mismatch
DOI: 10.1016/j.ejca.2012.01.019
Abstract: The world faces an unprecedented growth in cancer incidence over the next fifty years, the majority of the burden falling on low-middle income countries. At the same time as the changing dem...
|
R. Sullivan,
L. Homberg,
A.D. Purushotham
|
Discussion
(In Press Corrected Proof)
|
15 February 2012 |
|
Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease?
DOI: 10.1016/j.ejca.2012.01.026
Abstract: Background: A competing risks analysis was undertaken to identify subgroups at greatest risk of dying from prostate cancer (PC) after definitive external beam radiation therapy (RT)±androgen...
|
Michelle M. Kim,
Karen E. Hoffman,
Lawrence B. Levy,
Steven J. Frank,
Thomas J. Pugh,
Seungtaek Choi,
Quynh N. Nguyen,
Sean E. McGuire,
Andrew K. Lee,
Deborah A. Kuban
et al.
|
Full-length article
(In Press Corrected Proof)
|
15 February 2012 |
|
Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma
DOI: 10.1016/j.ejca.2012.01.015
Abstract: Hepatocellular carcinoma (HCC), a malignancy caused mainly by chronic infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), is a highly fatal disease. Apart from clinical pa...
|
Liping Chen,
Qi Zhang,
Wenjun Chang,
Yan Du,
Hongwei Zhang,
Guangwen Cao
et al.
|
Full-length article
(In Press Corrected Proof)
|
13 February 2012 |